Skip to main content
8 March 2021
Last updated:
Monday 8 March 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
    • News
    • Appointments
    • Events
  • About MedNous
  • Research Directory
  • Contact Us

News

Targovax oncolytic virus continues to benefit

Tuesday 23 February 2021
Country

Norway

An experimental oncolytic virus therapy in clinical development by Targovax ASA has continued to show a survival benefit for patients with malignant pleural mesothelioma 21 months after treatment. At follow-up, half of the patients in the first-line treatment group were still alive and median overall survival had not been reached, the company announced on 23 February.

Read more

AZ withdraws Imfinzi indication

Monday 22 February 2021
Country

United Kingdom

AstraZeneca Plc has voluntary withdrawn a bladder cancer indication for its checkpoint inhibitor Imfinzi (durvalumab) in the US, which was given an accelerated approval in 2017 but failed to show the required efficacy in a follow-up study. The Food and Drug Administration awards accelerated approvals to certain drugs, based on surrogate endpoints, but confirmation of clinical benefit needs to be verified in subsequent trials.

Read more

A new chapter for argenx

Monday 22 February 2021
Country

Netherlands

In just 12 years – the time it takes to develop a new chemical entity – argenx NV has grown from Dutch start-up into an internationally recognised biopharma enterprise. The company has a portfolio of wholly-owned and partnered antibody therapeutics, the first of which has been submitted for review to the US Food and Drug Administration. On 5 February, it announced gross proceeds of $1.15 billion from a global share offering, managed by J.P. Morgan and three other leading US financial institutions.

Read more

Evox completes Series C financing

Monday 22 February 2021
Country

United Kingdom

Less than a year after signing a lucrative licensing deal with Eli Lilly and Co, UK-based Evox Therapeutics Ltd has completed a Series C financing round to advance therapeutics based on exosomes into the clinic. The £69.2 million financing was led by Redmile Group, a US hedge fund, which was joined by the new investors OrbiMed Healthcare Fund Management and the Invus Group LLC.

Read more

Consolidation at Galapagos

Friday 19 February 2021
Country

Netherlands

Galapagos NV ended 2020 with a strong balance sheet but a reconfigured pipeline following its decision, together with partner Gilead Sciences Inc, to abandon plans to pursue a US marketing authorisation for Jyseleca (filgotinib), its small molecule drug for rheumatoid arthritis. The Food and Drug Administration turned back the application in August because of concerns about its benefit/risk profile at a dose of 200 mg. The two companies dropped plans for a US filing in December.

Read more

Centessa Pharmaceuticals is launched

Friday 19 February 2021
Country

United Kingdom

The Medicxi investment group has launched Centessa Pharmaceuticals Ltd, a new pharmaceutical company that brings together a group of diverse assets in order to develop them at scale with oversight from experts in the field. The launch marks a new stage in the Medicxi investment model that focuses on developing new drugs from single assets with a minimum of infrastructure in order to increase productivity and improve the return on investment.

Read more

Imcyse extends Series B financing

Thursday 18 February 2021
Country

Belgium

Imcyse SA has raised an additional €21.3 million in Series B financing in order to advance its pipeline of immunotherapy compounds and simultaneously brought Pfizer Inc on board as a shareholder. Earlier, Imcyse announced a licensing deal with Pfizer to develop a preclinical asset for rheumatoid arthritis.

Read more

Novartis, Gates Foundation to collaborate on gene therapy

Wednesday 17 February 2021
Country

Switzerland

Novartis and the Bill & Melinda Gates Foundation have announced plans to work together to develop an in vivo gene therapy for sickle cell disease, one of the oldest known and most common genetic disorders. The project will pool the Swiss company’s drug discovery expertise with the Gates Foundation’s charitable healthcare mission. A therapy developed by the collaboration would be distributed to low and middle-income countries.

Read more

Immunic drug shows activity in moderate Covid-19

Wednesday 17 February 2021
Country

Germany

A small molecule drug being developed by Immunic Inc has shown evidence of clinical activity in hospitalised patients with moderate Covid-19 disease, the company announced on 17 February. The finding, from a Phase 2 trial, suggests that the drug, IMU-838, may have application in patients aged over 65 years, as well as preventing long-term Covid-19 symptoms such as fatigue.

Read more

Lynparza to be reviewed early

Wednesday 17 February 2021
Country

United Kingdom

Lynparza (olaparib) has passed an important threshold in a Phase 3 trial of patients with early breast cancer with the result that it will undergo a primary analysis for efficacy earlier than planned. This follows a recommendation by the trial’s independent data monitoring committee which concluded that the drug has the potential to achieve a sustainable and clinically relevant treatment effect in patients, according to the sponsors AstraZeneca Plc and Merck & Co Inc.

Read more

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Microbiotica expands management team
Wednesday February 10 2021
Philippe Dro joins Scenic Biotech as independent chairman
Wednesday February 10 2021
NOXXON announces senior appointment to its new advisory board
Wednesday February 10 2021
Wendy Levin joins Biofidelity as chief medical officer
Wednesday February 10 2021
VarmX appoints Gerard Short as chief medical officer
Wednesday February 10 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.